Brinzolamide

Brinzolamide (AL-4862) is a selective carbonic anhydrase II inhibitor with anIC50 value of 3.2 nM. Brinzolamide hydrochloride reduces intraocular pressure (IOP) by inhibiting ciliary CA-II and decreasing atrial fluid secretion. Brinzolamide can be used in glaucoma disease research[1][2].

Product Specifications

CAS Number

[138890-62-7]

Product Name Alternative

AL-4862

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Carbonic Anhydrase

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease

Field of Research

Neurological Disease; Others; Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/Brinzolamide.html

Purity

99.91

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O=S(C(S1)=CC2=C1S(N(CCCOC)C[C@@H]2NCC)(=O)=O)(N)=O

Molecular Formula

C12H21N3O5S3

Molecular Weight

383.51

Precautions

H302, H315, H319, H335

References & Citations

[1] Vatsala Naageshwaran, et al. Comprehensive Ocular and Systemic Pharmacokinetics of Brinzolamide in Rabbits After Intracameral, Topical, and Intravenous Administration. J Pharm Sci. 2021 Jan;110 (1) :529-535.|[2] Sara M.Smith, et al. Tolerability, pharmacokinetics, and pharmacodynamics of a brinzolamide episcleral sustained release implant in normotensive New Zealand white rabbits, Journal of Drug Delivery Science and Technology, Volume 61,2021,102123, ISSN 1773-2247